Index*

ACTH
"big ACTH", 175
"little ACTH", 175
Acetyl strophanthinid, radioimmunoassay, 221
Adenylate cyclase activity, measurement by radioimmunoassay, 312
beta-Adrenergic binding sites
catecholamine assay vehicle, 259
heart muscle membrane fractions, 259
Adrenergic receptors, current concepts, 259
alpha-Adrenergic receptors, catecholamines, 261
beta-Adrenergic receptors, catecholamines, 261
Aldosterone, 249
antibodies, 255
differs from corticosterone, 255
(disc.), 269
measurement, 249, 254
methods for determination in plasma, 254
precursor, 255
radioimmunoassay, 255
Aliphatic amines, proteins with carbodiimides as reagents, 275
Aminophenyl derivatives, phenol conversion to active reagents, 276
Androgens
radioiodinated antitumor, use in immunotherapy (disc.), 359
radioligand methods of measurement, 190, (table), 193
secreted from ovary, 195
Angiotensin
antibodies, 249
assay specificity, 249
determination in plasma, 250
measurement, 249
Angiotensin II
formation rate and converting enzyme concentration, 252
generation rate, 253, 254
Angiotensin generation rate, renin concentration, 250
Angiotensinase
angiotensin antisera (disc.), 270
inhibitors, 250
Antibodies
barbiturates, 281
cell structure study, 343
investigative potential, 216
metabolism study with, 343
morphine, 281
prostaglandin. See Prostaglandin antibodies
radiiodinated antitumor, use in immunotherapy (disc.), 359
role in
cardiovascular diagnosis, 215
cardiovascular research, 215
cardiovascular therapy, 215
serotonin, 281
specific pharmacological and toxic effects of cardiac glycosides reversed by, 239
removal of biologically active substances from mammalian cells, 241
Antibody affinity
antigenic determinant, 319, (table), 320
distribution, 319, 321
effect of antigenic competition, 322, (table), 323
Antibody production, pooled sera vs. serum from individual animals (disc.), 315
Antibody specificity, comment on, 278
Antibody synthesis, selection theory, 320
Antigen-antibody complexes, dissociation, adverse effects (disc.), 269
Antigenic conjugates, synthesis, 293, (table), 294
Antihapten antibody, effect of antigen dose and time after immunization, 319, (table), 320
Antiprostaglandins
applications, 293
specificities, 293
Archer, J. A. See Gorden et al., 179
Aspirin, inhibition of production of prostaglandins, 303, 304

Background
practical, 161
theoretical, 161
Barbital-14C, competition for binding sites (tables), 286, 287
Barbiturates
antibodies, 281
antibody specificity, 285
habituation, 284
method of quantitative analysis, 284
radioimmunoassay, 284, 285
tolerance, 284
Berkowitz, Barry. See Spector et al., 281
Bloom, Floyd E., H. James Wedner and Charles W. Parker. The use of antibodies to study cell structure and metabolism, 343
Bresnick, Edward. Report on the discussion of the third session, 315

* Italic numbers denote reference to illustration in text.
Carbodiimides

Callabresi, Paul. Report on the discussion of the fourth session, 359

Cancer, immunotherapy, 325

Cardiac glycosides

Carboxylic acids

Cardiovascular applications, 215

radioimmunoassay of drugs and hormones affecting, 215

role of antibodies in diagnosis, therapy, and research, 215

physiological receptors in diagnosis, therapy, and research, 215

INDEX

Butler et al.—continued

the pharmacological and toxic effects of cardiac glycosides by specific antibodies, 239

Catechol compounds, binding inhibitors, 264

Catecholamines, 259

adenylate cyclase activity, 262, 266

adenylcyclase system, activation after binding (disc.), 270

adrenergic binding sites

non-specific interfering substances, 267

potential application, 265

sensitivity, 266, 268

specificity, 265

beta-adrenergic binding site, 259

adrenergic receptors, 259

beta-adrenergic receptor protein for measurement, 216

binding requirements, 265

binding reversible, 262

biological activity, requirements, 265

biological binding (table), 262

biological binding mechanisms, 259, 261, (table), 262

binding non-covalent, 262

cardiac muscle, binding site, 262

radioreceptor assay, 267

precision, 267

rapidity, 267

simplicity, 267

sensitive assay methodology, 259

specific assay methodology, 259

specificity of site, 262, 263

tritium-labeled, binding in vitro, 261, (table), 262

uptake mechanism (table), 262

Catecholamine receptor

affinity after denervation (disc.), 270

alpha-adrenergic, 261

beta-adrenergic, 261

metabolic effects, 261

species variation, 261

Cell structure, antibodies used to study, 343

Chloramphenicol, specific antibodies, 275

Corpus luteum function

control, 199

length of, 203

Cyclic nucleotide immunoassay

adenosine 3',5'-monophosphate, 310, 311

adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate, simultaneous assay, 311, (table), 312

antisera with minimal cross reactivity, 311

guanosine 3',5'-monophosphate measuring problems in tissues and body fluids, 312

immunogen preparation, 310

reagent preparation, succinyl 2'O-cyclic nucleotides, 309

sensitivity, 310

2'O-succinyl cyclic nucleotide tyrosine methyl ester, synthesis of, 310

tissue analysis, 310
Digoxin-specific antibodies—continued
pharmacological antagonists in digoxin action
mechanism study, 239
pharmacological antagonists in digoxin intoxication
reversal, 239
production, 240
properties, 240
Digoxin-specific antiserum
effect on cellular digoxin (table), 242
potassium influx restoration (table), 242
Digoxin-toxic arrhythmias, reversal of, 244
H-Dihydromorphine
competition for binding site (table), 282, 283
Drug protein conjugates, preparation for immunological studies, 271
Drug toxicity, modified by antibodies against haptenic drug, 284
Drugs
circulating levels, estimation of, 290
interaction with receptors, 290
Dyrenfurth, I. See Van De Wiele and Dyrenfurth, 189
Enzyme activity, converting, effect on angiotensin II formation, 252
Enzymes, inhibition by antibodies, 283
Epinephrine, measurement, 259
Epinephrine binding, adenylcyclase system, activation (disc.), 270
DL-10,11-Epoxyfarnesoic acid coupled to protein, 274, 274
Erlanger, Bernard F. Principles and methods for the preparation of drug protein conjugates for immunological studies, 271
Erythrocyte receptor, digoxin (disc.), 269
Estradiol, radioligand methods for measurement of, 189, (table), 192
Estragen, radioligand methods of measurement, 189, (table), 192
Estrone, radioligand methods of measurement, 189, (table), 192
Flynn, Edward J. See Spector et al., 281
Follicle stimulating hormone, radioimmunoassay, 189, (table), 190
Franklin, Edward C. Discussion of the second session, 269
Gardner, Jerry D. See Butler et al., 239
Gastrin, 173
“big gastrin”, 173
Zollinger-Ellison tumors, 174
“big, big gastrin”
newer immunoreactive form, 175
pernicious anemia, 175
Zollinger-Ellison syndrome, 175
radioimmunoassay, standard curve, 164
immunoreactive
Glycoside. See also Digoxin
cardiac. See Cardiac glycosides
digitalis. See Digitalis glycosides
Gonadotropin
interrelationships with steroids, 189
oscillatory pattern of secretion, control of, 204
Gorden, P., J. R. Gavrin, III, C. R. Kahn, J. A.
Archer, M. Lesniak, C. Hendricks, D. M.
Neville, Jr. and J. Roth. Application of radioreceptor assay to circulating insulin,
growth hormone, and to their tissue receptors in animals and man, 179
Growth hormone
“big”, 184
binding to lymphocyte receptors (disc.), 211
biological effects on tissues, 184
biological properties, assessment of, 179, 180
immunological properties, assessment of, 179, 180
“little”, 184
radioimmunoassay, 179
radioreceptor activity, 184, 185
radioreceptor assay, 182
requirements, 182
somatotropin, 182
Guanylate cyclase activity, measurement by radioimmunoassay, 312
Haber, Edgar. The role of antibodies and physiological receptors in cardiovascular diagnosis, therapy, and research, 215
Haber, Edgar. See Smith and Haber, 219
Hapten-protein conjugates, antibodies to biologically interesting compounds, 278
Haptens
aldehydes as haptenic determinant groups, 277
aliphatic amines, 275
amino acids of bovine serum albumin, 272, 272
amino groups, 274
linked to protein carriers with glutaraldehyde, 275
aminophenyl derivatives, 276
aromatic amines, 275
carbodiimides, 273
carboxyl groups, 273
chloroethanes, 275
critical number attached to carrier (disc.), 317
hemisuccinates, 275
hydroxyl groups, 275
hydroxyl methods, miscellaneous, 276
ketones as haptenic determinant groups, 277
low molecular weight, used as determinant groups, 277
miscellaneous carboxyl methods, 274
mixed anhydride procedure, 273, 275
morpholine ring (disc.), 317
nature of, 273
oxidation to
carboxyl, 276
dialdehydes, 276
response when coupled to polypeptides (disc.), 317
response when coupled to protein (disc.), 317
Hendricks, C. See Gorden et al., 179
Heroin, antibodies to (disc.), 318
Heroin conjugate, addict immunization (disc.), 318
Hormone, growth. See Growth hormone
Hormone, peptide. See Peptide hormone
Hormone receptor
biological response, 260
discriminatory function, 290
membrane bound, 290, 290, 291
radio-receptor assays (table), 291
receptor function, 290
selective binding, 290
Hormone receptor binding
biological specificity, 290
reversible process, 290
specificity, 290
Hormones
inhibition of biological activity by antibodies, 283
interaction with receptors, 290
Hydroxyl methods
protein conjugates, 276
Immune apparatus, important role in resistance to tumor growth, 325
Immune resistance
involvement of lymphoid system, 327
limitations, 325
Immune response
afferent arm, 326
problems, 328
characteristics, 319
depression in magnitude, 320
efferent arm, 326, 327
antibodies and antigen-antibody complexes, 331
delivery problem, 329
problems, 329
tumor antigens, circulating, 329
genetic influences, 328
B-lymphocytes, 319
immunological tolerance, 320, (table), 320
levels, 325
non-specific depression, 322, (table), 323
effect on antibody affinity, 322
non-specific modifications, 322
effect on average affinity of antibody, 323
normal components, 326
partial tolerance, 328
passive antibody, 322
specific modifications, effect on average affinity of antibody, 323
tolerance induction, effect on antibody affinity (tables), 320
treatment of cancer, 325
treatment with heterologous antilymphocyte serum, 322
tumor antigen
host responsiveness, 328
presentation to host, 328
properties, 328
use of cytotoxic drugs, 322
variations in antigen dose, 320
variation of magnitude, 319
Immunoadsorption, protein in vivo, solid phase, 337
Immunoonassay
compounds to which procedure does not apply, 215
gastrin, standard curve, 164
Immunocytochemistry
application, 343
anti-cAMP immunoglobulin, 349
cytopathology, 343
biosynthetic cell antigens, localization, 347, (table) 347
catecholamines, localization, 354
classes of molecules successfully localized by this methodology, 343
concepts which allow technique to be applied to analysis of normal cell structure and metabolism, 343
cyclic 3',5'-adenosine monophosphate immunofluorescent staining, 349
patterns in stimulated lymphocytes, 349
stimulated neurons, 351
cyclic 3',5'-adenosine monophosphate, localization, 348
after stimulation, 349
in human lymphocytes, 350
epinephrine, localization, 354
enzymatic macromolecules, localization, 346
histamine, localization, 354
immunocytochemical controls, 346
immunoglobulin labels, localization, 344
intracellular enzymes, localization (table), 346
non-enzymatic tissue macromolecules, localization, 347
prostaglandins, localization, 354
small molecule localization, technical requirements, 343
structural cell antigens, localization, 347, (table), 347
tissue antigen, localization of, 343
INDEX

Immunocytochemistry—continued
  tissue localization, alternative approaches, 354
tissue preparation, 345
Immunocytochemistry, cell surface macromolecules, localization, 348
Immunoglycan labels, localization, 344
Immunotherapy
  activation of non-sensitized lymphocytes, 340
  antagonistic interactions between cytotoxic agents and immunity, 340
  antibody-toxin conjugates, 338
  antigen-antibody complexes, selective removal, 336
  BCG, adjuvant to increase nonspecific resistance to tumors, 336
  blocking antigen, selective removal, 336
  conventional approaches, 335
  cytotoxic drugs and immune system, interrelationships, 340
cytotoxins, educated, 338
  enzymatic induction of tumor cells, 338, 359
general considerations, 334
  graft vs. host reaction, 336
  host-tumor relationship, 334
  immune reactants, improving delivery, 339
  immunization, active, 335
  indirect toxins, 338, (table), 338
  new approaches, 336
  non-specific amplification of immunity, 336
  passive immunization with conventional antibody, 336
  ribonucleic acid extracts from sensitized lymphocytes, 340
  sensitized allogenic lymphocytes, 336
  sensitized xenogeneic lymphocytes, 336
  synergistic interactions between cytotoxic agents and immunity, 340
tumor growth control, 341
Indomethacin
  effect on proteinuria in nephrotic syndrome (disc.), 317
  inhibition of prostaglandin production, 303, 304
Insect juvenile hormone
coupled to protein, 274, 274
  N-hydroxysuccinimide esters, 274, 275
Insulin
  "big, big insulin", 172, 173
  "big, big", structure (disc.), 210
  binding to lymphocyte receptors (disc.), 211
  biological properties, assessment of, 179, 180
  central nervous system metabolic role (disc.), 212
  "first" among protein hormones, 172
  immunological properties, assessment of, 179, 180
  initial action, 179
  lymphocyte binding (disc.), 213
  radioimmunoassay, 179
radioceptor assay, 179
  receptor site systems (disc.), 212
  tissues that bind (table), 180
Insulin resistance
  human, 186
  insulin-receptor interaction, 186
  obesity, 185, 186
Kahn, C. R. See Gorden et al., 179
La Du, Bert. Introduction, 157
Lefkowitz, Robert J. Isolated beta adrenergic binding sites: a potential assay vehicle for catecholamines, 259
Lesniak, M. See Gorden et al., 179
Levine, Lawrence. Antibodies to pharmacologically active molecules: specificities and some applications of antiprostaglandins, 293
Ligand binding, characteristic features, 259
Lindenbaum, John. Bioavailability of digoxin tablets, 229
Luteinizing hormone
  oscillatory nature, 197, 199
  Premarin effects (disc.), 212
  radioimmunoassay, 189, (table), 190
Malignancy. See Cancer, Tumor
Mandel, William J. See Butler et al., 239
Menstrual cycle, mechanism of control, 196
Metabolism, antibodies used to study, 343
Morphine
  analgesic effect, 284, (table), 284
  analgesic potency, reduction of (disc.), 318
  antibodies, 281
  effect of synthetic surrogates, 283, (table), 283
  Morphine derivatives
  coupled to bovine serum albumin, 281
  Morphine immunization, biological responses (disc.), 316
  Morphine immunogens, specificity of antibodies, 281
  Morphine-protein conjugates antigenicity, 281
  morphine derivatives used in preparation of, 281, 282
  preparation of, 281
Neville, D. M., Jr. See Gorden et al., 179
Noradrenaline, measurement, 259
  3H-Norepinephrine, blocking compounds, 262, (table), 264
  Norepinephrine binding, Scatchard plot, 265, 266
  Nucleoside-protein conjugate, periodate method, 276, 276
  Nucleotide-protein conjugates, periodate method, 276, 276
  Nucleotides, cyclic. See Cyclic nucleotides
INDEX

Opiate alkaloid
   brain concentrations reduced by antibodies, 284
   radioimmunoassay, 281
Ouabain, radioimmunoassay, 221
Ovarian hormone research, 191, 194
Ovulation requirements (disc.), 212
Parathyroid hormone, immunochemical heterogeneity, 170, 171
Parker, Charles W. See Bloom et al., 343
Parker, Charles W. The immunotherapy of cancer, 325
Penicillenic acid, conjugated to protein, 277
Peptide hormone
   heterogeneity, problems of, 161
   radioimmunoassay applied to heterogeneity problems, 161
Peptide synthesis, mixed anhydride procedure, 273, 275
Pernicious anemia, immunoreactive gastrin, 173
Peekar, Bernard. See Spector et al., 281
Pharmacological applications, 271
Physiological receptors, role in cardiovascular diagnosis, 215
cardiological research, 215
cardiovascular therapy, 215
Plasma barbiturate concentration, radioimmunoassay, 287, 288
Plasma renin activity, measure of renin-angiotensin system, 254
Polylysinic carrier, antibody response (disc.), 315
Polyopeptide carrier, advantage over protein in problem of heterogeneity (disc.), 315
Poulsen, Knud. Measurements of renin-angiotensin-aldosterone, 249
Progestosterone, assay, 189, (table), 190
Proinsulin
   bovine, 181
   characteristics, 181
   content in insulin in plasma, 172
discovery, 172
porcine, 181
   methods to distinguish, 181
Prostaglandin antibodies
   applications of, 301
   metabolic enzyme activity, measurement of, 301
   usefulness for assay, 294
   variation of activities in different species, 302, (table), 303
Prostaglandin antigen-antibody reactions, specificities, 294
Prostaglandin antiprostaglandin reactions, specificities, 293
Prostaglandins
   biosynthesis, 293
   bone resorption stimulating activity, 303, (table), 305
cross reactions, 294
degree of unsaturation, 293
description of, 293
fatty acids conversion to, 293
human synovial fluids, assay of, 304
identification, 297-300
inhibition, 295, 297
   by aspirin, 303, 304
   by indomethacin, 303, 304
   levels of type E (disc.), 318
metabolism in man, 294, 296
pharmacologically active antibodies, 293
protein transport in kidney (disc.), 317
quantitation, 297-300
radioimmunoassay, 294
serological specificity (table), 297
specificity, subsites contributing to, 297
structure, 293, 295
   tumor, measurement in (disc.), 316
types, 293
   variation to specificity of antibodies (disc.), 315
Protein binding assays, 259
   binding site availability, 259
Protein carrier
   antibody to, 271
   choice of, 272
   fibrinogen, 272
globulin fractions, 272
   hemocyanin, 272
   original specificity, 271
   ovalbumin, 272
polypeptide possible advantage in problem of heterogeneity (disc.), 315
   serum albumins, 272
Protein conjugates
   acetylation of serum albumin amino groups, 271
   characterization, 278
   chloramphenicol, 275
diazonium compounds, 271
diagation procedure, 275
   history, 271
   hydroxyl methods, 276
radioactive hapten, 278
   trinitrobenzene sulfonic acid as reagent, 278
Protein
   carboxylic acid derivatives, reaction, 276
   DL-10,11-epoxyfarnesioic acid coupled to, 274, 274
Radioimmunoassay. See also Radioreceptor assay
accomplishments, 161
adenosine 3',5'-monophosphate, 309
adenylate cyclase activity measurement, 312
aldosterone, 255
angiotension, 249
antibody production, species variation, 166
antigen separation technique (table), 164
   applications
   endocrinology, 161, 176
   other fields, 162, 176
Radioimmunoassay—continued
  barbiturates, 284, 285
  classical dilution principle (disc.), 209
  compared with competitive assay, 209–210
  requirements (disc.), 209
  competitive assay, requirements (disc.), 210
  corpus luteum, functional control, 199
  cyclic nucleotides, 309
  development, 271
  digitalis glycosides, 219
  drugs affecting cardiovascular system, 215
  follicle stimulating hormone, 189, (table), 190
  gastrin
    sensitivity comparison, 168
    standard curve, 164
  gonadotropin measurement, 189
  gonadotropin releasing hormone, 204
  growth hormone, physiology and pathophysiology, 179
  guanosine 3′,5′-monophosphate, 309
  guanylate cyclase activity, measurement, 312
  history (disc.), 209
  hormonal cross-reactivity, 166
  species differences, 166
  hormones affecting cardiovascular system, 215
  inosine 3′,5′-monophosphate, 309
  insulin
    “first” among protein hormones, 172
    physiology and pathophysiology, 179
    species differences, 166, 168, 169, 170
  luteinizing hormone, 189, (table), 190
  methodology, 162
  antigen separation techniques, 162, (table), 164
    (disc.), 209
  essential requirements, 162
  radioisotope for labeling, 166
  non-hormonal factors, 176
  non-hormonal substances (table), 163
  non-peptidial hormones (table), 163
  non-specific binding, definition (disc.), 210
  parathyroid hormone, immunochemical heterogeneity, 170, 171
  peptide hormone heterogeneity, 161
  peptide hormones (table) 163
  plasma barbiturate concentrations, 287, 288
  practice, essential requirements, 162
  principle
    application, 161, 162, (table), 163
    specific reactor is specific antibody, 162
  problems, 178
  non-specificity, 169
  procedures
  problems caused by plasma of immunologically related species, 168
  validation of hormonal cross-reactivity (table), 167
  validation of non-hormonal effects (table), 167
  proinsulin, species differences, 168
  prostaglandins, 294
  requirements, 166
  sensitivity comparison, 165
  sensitivity limited by, 163
  sensitivity requirements, 162
  separation of antibody-bound and free-labeled antigen (table), 164
  serotonin, 288, 290
  substances measured by (table), 163
  suitable antibody, sine qua non, 165
  uridine 3′,5′-monophosphate, 309
  validation of procedures, 166, 167, (table), 167
  Radioimmunoassay technique, immunological procedures facilitated by, 281
  Radioligand methods, gonadotropin and steroid measurement, 189
  Radioreceptor assay
  application to
    growth hormone, 179
    insulin, circulating, 179
    catecholamines, advantages, 267
    receptor disease, 185
    animal model, 185
    human insulin resistance, 186
  Radioreceptor system, essential ingredients, 179
  Receptors
  binding function (disc.), 212
  biological process, activation of (disc.), 212
  catecholamine. See Catecholamine receptor
  erythrocyte. See Erythrocyte receptor
  hormone. See Hormone receptor
  hormone binding to tissue, biological activity (disc.), 212, 213
  major functions (disc.), 212
  physiological. See Physiological receptors
  Renin, 249, (disc.), 269
  measurement, 249
  Renin activity, plasma, 250
  determination methods, 250
  Renin-angiotensin-aldosterone, physiological point of view, 249
  Renin-angiotensin system
    aldosterone measurement, 254
    measurement, 254
  Renin concentration
    measurement, 251
    plasma renin activity not a measure for, 254
  Renin inhibitors, presence in plasma, 251, 263
  Renin substrate concentration, angiotensin generation rate, 250
  Renin system, 249
    diagram, 250
    renal and essential hypertension, 249
    Roth, J. See Gorden et al., 179
  Scatchard plots
    equilibrium constants (disc.), 270
    norepinephrine binding, 265, 266
INDEX

Tumor cell
biochemical properties, 334
cellular immune resistance, blocking factor, 331
enzymatic iodination, 338, 339
resistance to immune destruction, 332
structural properties, 334
surface antigen density, 332
Tumor cell selection, antigenic modulation, 333
Tumor growth
antibodies, enhancing effect, 331
characteristics, 334
immune resistance, failure, 326
inhibition, 325
non-cytotoxic antibody, stimulus to resting tumor cells, 331
site of origin, an important variable, 328
Tumor immunology, fundamental observations, 325
Tumors, increased incidence with impaired cellular immunity, 329
Tumor specific antigen, distribution, 332
Tumor therapy
chemotherapy, capacity, 325
immune resistance, 325
immune response, capacity, 325
radiotherapy, capacity, 325

Van de Wiele, R. L. and I. Dyrenfurth. Gonadotropin-steroid interrelationships, 189
Watson, John F. See Butler et al., 239
Wedner, H. James. See Bloom et al., 343
Yalow, Rosalyn S. Dedication, 159
Radioimmunoassay methodology: application to problems of heterogeneity of peptide hormones, 161
Zollinger-Ellison syndrome,
“big gastrin” from, 174
immunoreactive gastrin, 173

Schmidt, Donald H. See Butler et al., 239
Sebacoyl dichloride, alcohol conversion to acid chlorides, 277
Serotonin
antibodies, 281
association with emotional stability, 288
inhibition of binding, 289, 329
physiological role in human disease, 288
radioimmunoassay, 288
specific antibodies, 288
specificity of radioimmunoassay, 290
Serotonin analogues, specificity of radioimmunoassay, 290
\textsuperscript{3}H-Serotonin antibody complex, competitive inhibition of formation, 289
Serotonin-protein conjugate, preparation by Mannich reaction, 277, 277
Siskind, Gregory W. Manipulation of the immune response, 319
Skelton, C. Lynn. See Butler et al., 239
Smith, Thomas W. and Edgar Haber. Clinical value of the radioimmunoassay of the digitoxis glycosides, 219
Somatomedin, effects on growth hormone, 182
Species differences in antibody affinities (disc.), 361
Spector, Sydney, Barry Berkowitz, Edward J. Flynn and Bernard Peskar. Antibodies to morphine, barbiturates, and serotonin, 281
Steiner, Alton L. Radioimmunoassay for the cyclic nucleotides, 309
Steroids
cross reactions (disc.), 315
interrelationships with gonadotropins, 189
Steroid dynamics, hormone secretory and production measurement, 192
Steroid-protein conjugates
antisteroid antibodies, 272
bovine serum albumin as carrier, 272, 272
dinitrophenylation technique, 278
hemisuccinates, 275
Tissue antigen, localization of, 343
Tumor antigens, metabolism, 328